Wedbush Initiates Coverage On Farfetch with Neutral Rating, Announces Price Target of $38
Wedbush analyst Tom Nikic initiates coverage on Farfetch (NYSE:FTCH) with a Neutral rating and announces Price Target of $38.
10 Consumer Discretionary Stocks With Unusual Options Alerts In Today’s Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Unusual trading activity could push option prices to hyperbolic or underperforming levels.
Cathie Wood’s ARK Invest Posts Fund Purchases For Wednesday, Sept. 8, 2021: PATH, NVTA, FATE, PD, DE, MKFG, KMTUY, SPFR, ROKU, SPLK, KVSB, ADPT, SLGC, VCYT, PSNL, RPTX, ETSY, FTCH, STNE, Z, JD, HEI, BLDE, AVAV
UiPath (PATH) - 1,382,967 Shares
Invitae (NVTA) - 616,413
Fate Therapeutics (FATE) - 129,739
PagerDuty (PD) - 55,058
Deere & Co (DE) - 37,991
Markforged (MKFG) - 600,664
Komatsu (KMTUY) - 96,118
Jaws
‘Fast Money Halftime Report’ Picks For September 2
On CNBC's "Fast Money Halftime Report," Pete Najarian said he bought $15.50-strike calls in SoFi Technologies Inc (NASDAQ: SOFI). He noticed some call activity in the name.
Wells Fargo Upgrades Farfetch to Overweight, Raises Price Target to $55
Wells Fargo analyst Ike Boruchow upgrades Farfetch (NYSE:FTCH) from Equal-Weight to Overweight and raises the price target from $45 to $55.
Cathie Wood’s ARK Invest Posts Fund Purchases For Friday, Aug. 20, 2021: FATE, SRNG, BEAM, SGFY, TSP, VCYT, PLTR, AVAV, MKFG, BLDE, SPFR, FTCH, GENI, KVSB, LPSN, SMFR, MASS, RPTX, QSI, ZY, PATH
Fate Therapeutics (FATE) - 397,896
Soaring Eagle Acquisition Corp (SRNG) - 273,629
Beam Therapeutics (BEAM) - 40,061
Signify Health (SGFY) - 18,900
Tusimple Holdings (TSP) - 1,970
Veracyte (VCYT) -
Credit Suisse Maintains Outperform on Farfetch, Lowers Price Target to $80
Credit Suisse maintains Farfetch (NYSE:FTCH) with a Outperform and lowers the price target from $84 to $80.